$383.02
+8.37
(+2.23%)
As of Oct 15, 2026, 11:03 PM EDT
Price history
West Pharmaceutical Services (WST) is trading up at $383.02 (+2.23%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
West Pharmaceutical Services revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.51B | $1.60B | $1.72B | $1.84B | $2.15B | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Growth (year over year) | +7.8% | +6.0% | +7.4% | +7.1% | +16.7% | +31.9% | +2.0% | +2.2% | −1.9% | +6.3% |
| Gross profit | $501.4M | $512.9M | $545.4M | $605.7M | $767.8M | $1.18B | $1.14B | $1.13B | $998.5M | $1.10B |
| Gross margin | 33.2% | 32.1% | 31.8% | 32.9% | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating income | $195.2M | $225.8M | $240.3M | $296.6M | $406.9M | $752.3M | $734.0M | $676.0M | $569.9M | $584.9M |
| Operating margin | 12.9% | 14.1% | 14.0% | 16.1% | 19.0% | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Net income | $143.6M | $150.7M | $206.9M | $241.7M | $346.2M | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| Net margin | 9.5% | 9.4% | 12.0% | 13.1% | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| EPS (diluted) | $1.91 | $1.99 | $2.74 | $3.21 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Balance sheet | ||||||||||
| Cash and equivalents | $203.0M | $235.9M | $337.4M | $439.1M | $615.5M | $762.6M | $894.3M | $853.9M | $484.6M | $791.3M |
| Total assets | $1.72B | $1.86B | $1.98B | $2.34B | $2.79B | $3.31B | $3.62B | $3.83B | $3.64B | $4.27B |
| Total liabilities | $599.2M | $582.9M | $582.6M | $768.2M | $939.3M | $978.4M | $931.9M | $948.5M | $961.1M | $1.09B |
| Long-term debt | $226.2M | $197.0M | $196.0M | $255.0M | $252.9M | $208.8M | $206.7M | $72.8M | $202.6M | $202.8M |
| Shareholders' equity | $1.12B | $1.28B | $1.40B | $1.57B | $1.85B | $2.34B | $2.68B | $2.88B | $2.68B | $3.18B |
| Cash flow | ||||||||||
| Operating cash flow | $219.4M | $263.3M | $288.6M | $367.2M | $472.5M | $584.0M | $724.0M | $776.5M | $653.4M | $754.8M |
| Capital expenditure | $170.2M | $130.8M | $104.7M | $126.4M | $174.4M | $253.4M | $284.6M | $362.0M | $377.0M | $285.9M |
| Free cash flow | $49.2M | $132.5M | $183.9M | $240.8M | $298.1M | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Dividends paid | $35.8M | $39.1M | $42.1M | $45.1M | $48.1M | $51.1M | $54.1M | $57.0M | $59.1M | $61.2M |
| Share buybacks | $52.2M | $74.4M | $70.8M | $83.1M | $115.5M | $137.1M | $202.8M | $438.3M | $560.9M | $134.0M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $746.9M | $748.8M | $698.0M | $766.5M | $804.6M | $805.0M | $844.9M | $872.3M |
| Growth (year over year) | −0.1% | +2.3% | +0.4% | +9.2% | +7.7% | +7.5% | +21.0% | +13.8% |
| Gross profit | $264.7M | $273.6M | $231.9M | $273.9M | $294.3M | $303.9M | $296.4M | $329.2M |
| Gross margin | 35.4% | 36.5% | 33.2% | 35.7% | 36.6% | 37.8% | 35.1% | 37.7% |
| Operating income | $161.3M | $159.6M | $107.0M | $153.7M | $167.6M | $156.6M | $177.1M | $179.1M |
| Operating margin | 21.6% | 21.3% | 15.3% | 20.1% | 20.8% | 19.5% | 21.0% | 20.5% |
| Net income | $136.0M | $130.1M | $89.8M | $131.8M | $140.0M | $132.1M | $138.8M | $154.0M |
| Net margin | 18.2% | 17.4% | 12.9% | 17.2% | 17.4% | 16.4% | 16.4% | 17.7% |
| EPS (diluted) | $1.85 | $1.78 | $1.23 | $1.82 | $1.92 | $1.82 | $1.92 | $2.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $490.9M | $484.6M | $404.2M | $509.7M | $628.5M | $791.3M | $521.4M | $435.8M |
| Total assets | $3.68B | $3.64B | $3.62B | $3.95B | $4.11B | $4.27B | $4.11B | $4.08B |
| Total liabilities | $923.0M | $961.1M | $935.1M | $1.02B | $1.05B | $1.09B | $1.12B | $1.09B |
| Long-term debt | $202.6M | $202.6M | $202.6M | $202.6M | $202.7M | $202.8M | $202.8M | $202.9M |
| Shareholders' equity | $2.75B | $2.68B | $2.68B | $2.93B | $3.05B | $3.18B | $2.99B | $2.99B |
| Cash flow | ||||||||
| Operating cash flow | $180.1M | $190.1M | $129.4M | $177.1M | $197.2M | $251.1M | $89.9M | $124.0M |
| Capital expenditure | $81.3M | $104.9M | $71.3M | $75.2M | $63.3M | $76.1M | $42.7M | $43.2M |
| Free cash flow | $98.8M | $85.2M | $58.1M | $101.9M | $133.9M | $175.0M | $47.2M | $80.8M |
| Dividends paid | $14.5M | $15.3M | $15.2M | $15.1M | $15.1M | $15.8M | $15.8M | $15.7M |
| Share buybacks | $52.4M | $54.4M | $133.5M | $500.0K | $0 | $0 | $297.6M | $156.7M |
From West Pharmaceutical Services's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About West Pharmaceutical Services
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.
Source: Wikipedia — West Pharmaceutical Services
- Headquarters
- Exton, Pennsylvania From SEC filings, Oct 2026
Recent News (12)
-
West to Host Third-Quarter 2026 Conference Call EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will releas…
-
West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide EXTON, Pa., Oct. 5, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation i…
-
Is West Pharmaceutical Services Stock Outperforming the Nasdaq?
Is West Pharmaceutical Services Stock Outperforming the Nasdaq?
-
Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?
Do You Believe West Pharmaceutical Services (WST) Represents a Tremendous Opportunity?
-
Are Wall Street Analysts Predicting West Pharmaceutical Stock Will Climb or Sink?
Are Wall Street Analysts Predicting West Pharmaceutical Stock Will Climb or Sink?
-
Mitrade Sponsors World Snooker Tour, Backing the Action Across Europe's Snooker Heartlands LIMASSOL, Cyprus, Aug. 27, 2026 /PRNewswire/ -- Mitrade, a CFD trading platform, is sponsoring the World Snooker Tour (WST) as its Official Trading Partner for the 2026/27 season. The move lands in a …
-
-
Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2 Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2
-
West Pharmaceutical Services Q2 Earnings Call Highlights West Pharmaceutical Services Q2 Earnings Call Highlights
-
West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary West Pharmaceutical Services, Inc. Q2 2026 Earnings Call Summary
-
West Reports Second-Quarter 2026 Results Raising Full-Year Net Sales and EPS guidance EXTON, Pa., July 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutio…
-
West Declares Quarterly Dividend EXTON, Pa., July 21, 2026 /PRNewswire/ -- On July 21, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug admini…
More Health Care stocks
- VEEV Veeva Systems
- VRTX Vertex Pharmaceuticals
- VTRS Viatris
- WAT Waters Corporation
- ZBH Zimmer Biomet
- ZTS Zoetis
- A Agilent Technologies
- ABBV AbbVie